Cormorant discloses 10.88% Bright Minds (DRUG) stake via funds

Rhea-AI Filing Summary

Cormorant Asset Management LP and Bihua Chen report beneficial ownership of 1,059,331 Bright Minds Biosciences common shares, representing 10.88% of the class. All voting and dispositive power over these shares is shared, with no sole authority reported.

The shares are held through Cormorant Global Healthcare Master Fund, LP and related Cormorant funds. The filers state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Bright Minds Biosciences Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

10919W405

(CUSIP Number)

01/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 10919W405

1

Names of Reporting Persons

Cormorant Asset Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,059,331.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,059,331.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,059,331.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.88 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 10919W405

1

Names of Reporting Persons

Bihua Chen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,059,331.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,059,331.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,059,331.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.88 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bright Minds Biosciences Inc.
(b)	Address of issuer's principal executive offices: 400 N Aberdeen Street, Suite 900, Chicago, IL 60642
Item 2.
(a)	Name of person filing: Cormorant Asset Management, LP Bihua Chen This statement is filed by (i) Cormorant Asset Management, LP, a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the shares directly held by the Cormorant Funds and (ii) Bihua Chen with respect to the shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
(b)	Address or principal business office or, if none, residence: 200 Clarendon Street, 52nd Floor Boston, MA 02116
(c)	Citizenship: Cormorant Asset Management, LP - Delaware Bihua Chen - United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 10919W405
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,059,331
(b)	Percent of class: 10.88%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,059,331
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,059,331 Shares reported herein for Cormorant Asset Management, LP ("Cormorant") represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Cormorant serves as the investment manager of the Master Fund. Bihua Chen serves as the managing member of GP, LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in a Prospectus filed by the Issuer on January 9, 2026 that there would be 9,732,161 Common Shares outstanding following the closing of a public offering described therein and (ii) a statement in a Current Report on Form 6-K filed by the Issuer on January 9, 2026 reporting that the public offering closed on January 9, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 4. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cormorant Asset Management, LP

Signature:	/s/ Bihua Chen
Name/Title:	Bihua Chen, Managing Member
Date:	02/06/2026

Bihua Chen

Signature:	/s/ Bihua Chen
Name/Title:	Bihua Chen
Date:	02/06/2026

Exhibit Information

Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on October 22, 2024

FAQ

What stake in Bright Minds Biosciences (DRUG) does Cormorant report?

Cormorant Asset Management LP and Bihua Chen report beneficial ownership of 1,059,331 common shares of Bright Minds Biosciences, equal to 10.88% of the outstanding class. This reflects their aggregate position held through Cormorant-managed investment funds.

How is voting power over Bright Minds (DRUG) shares held by Cormorant structured?

The filing states 0 shares with sole voting power and 1,059,331 shares with shared voting power. This means decisions to vote the shares are made collectively through the Cormorant funds rather than by Cormorant or Bihua Chen individually.

Who ultimately holds Bright Minds (DRUG) shares reported by Cormorant?

The shares are held by Cormorant Global Healthcare Master Fund, LP and other Cormorant funds. Cormorant Asset Management LP serves as investment manager, and Bihua Chen is managing member and general partner of related entities overseeing these investment vehicles.

Do Cormorant and Bihua Chen claim full beneficial ownership of DRUG shares?

The reporting persons disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest. This common disclaimer means they acknowledge economic exposure but not necessarily full ownership in all legal or regulatory contexts.

Are Cormorant’s Bright Minds (DRUG) shares held to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences, nor in connection with any transaction having that purpose or effect.

Which Cormorant fund holds more than 5% of Bright Minds (DRUG)?

Cormorant Global Healthcare Master Fund, LP, one of the Cormorant funds, has the right to receive or direct dividends or sale proceeds from more than 5% of Bright Minds’ common shares, according to the ownership description in the Schedule 13G/A amendment.